Cover Image
市場調查報告書

Lexicon Pharmaceuticals, Inc.的產品平台分析

Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 240929
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Lexicon Pharmaceuticals, Inc.的產品平台分析 Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 44 Pages
簡介

Lexicon Pharmaceuticals, Inc.ha是參與糖尿病和類癌症候群等疾病用醫藥品的藥物研發,研究的生物科技企業。

本報告提供Lexicon Pharmaceuticals, Inc.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Lexicon Pharmaceuticals, Inc.的基本資料

Lexicon Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Lexicon Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Lexicon Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Lexicon Pharmaceuticals, Inc.:開發中產品概況

  • 位於最終階段的開發中產品
    • 位於第三階段的產品/聯合治療模式
  • 位於臨床實驗階段的開發中產品
    • 位於第二階段的產品/聯合治療模式
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式

Lexicon Pharmaceuticals, Inc.:藥物簡介

  • telotristat etiprate
  • LX-1033
  • LX-2931
  • sotagliflozin
  • LX-7101
  • LX-2761
  • S100-A8

Lexicon Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

Lexicon Pharmaceuticals, Inc.:最近的開發平台趨勢

Lexicon Pharmaceuticals, Inc.:暫停中的計劃

Lexicon Pharmaceuticals, Inc.:企業發表

Lexicon Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04872CDB

Global Markets Direct's, 'Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Lexicon Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lexicon Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lexicon Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lexicon Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lexicon Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Lexicon Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lexicon Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lexicon Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lexicon Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lexicon Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lexicon Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lexicon Pharmaceuticals, Inc. Snapshot
    • Lexicon Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Lexicon Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Lexicon Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Lexicon Pharmaceuticals, Inc. - Pipeline Products Glance
    • Lexicon Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Lexicon Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Lexicon Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Lexicon Pharmaceuticals, Inc. - Drug Profiles
    • telotristat etiprate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-1033
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-2931
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotagliflozin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-7101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-2761
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S100-A8
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lexicon Pharmaceuticals, Inc. - Pipeline Analysis
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Target
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Lexicon Pharmaceuticals, Inc. - Dormant Projects
  • Lexicon Pharmaceuticals, Inc. - Company Statement
  • Lexicon Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lexicon Pharmaceuticals, Inc., Key Information
  • Lexicon Pharmaceuticals, Inc., Key Facts
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Lexicon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Lexicon Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Lexicon Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Lexicon Pharmaceuticals, Inc. - Phase III, 2014
  • Lexicon Pharmaceuticals, Inc. - Phase II, 2014
  • Lexicon Pharmaceuticals, Inc. - Phase I, 2014
  • Lexicon Pharmaceuticals, Inc. - Preclinical, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Lexicon Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Lexicon Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Lexicon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Lexicon Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top